These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34710359)

  • 1. The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study.
    Morin S; Moak HB; Bubb-Humfryes O; von Drehle C; Lazarus JV; Burrone E
    Lancet Public Health; 2022 Feb; 7(2):e169-e176. PubMed ID: 34710359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Projected savings through public health voluntary licences of HIV drugs negotiated by the Medicines Patent Pool (MPP).
    Juneja S; Gupta A; Moon S; Resch S
    PLoS One; 2017; 12(5):e0177770. PubMed ID: 28542239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of voluntary licences for hepatitis C medicines on access to treatment: a difference-in-differences analysis.
    Simmons B; Cooke GS; Miraldo M
    Lancet Glob Health; 2019 Sep; 7(9):e1189-e1196. PubMed ID: 31362914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intellectual property licensing of therapeutics during the COVID-19 crisis: lessons learnt for pandemic preparedness and response.
    Braimoh T; Burrone E; Gore C; Vijayaraghavan P
    Global Health; 2024 Jul; 20(1):52. PubMed ID: 38956614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voluntary licensing of long-acting HIV prevention and treatment regimens: using a proven collaboration- and competition-based mechanism to rapidly expand at-scale, sustainable, quality-assured and affordable supplies in LMICs.
    Gaayeb L; Das A; James I; Murthy R; Nobre S; Burrone E; Morin S
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26092. PubMed ID: 37439078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding access to biotherapeutics in low-income and middle-income countries through public health non-exclusive voluntary intellectual property licensing: considerations, requirements, and opportunities.
    Morin S; Segafredo G; Piccolis M; Das A; Das M; Loffredi N; Larbi A; Mwamelo K; Villanueva E; Nobre S; Burrone E
    Lancet Glob Health; 2023 Jan; 11(1):e145-e154. PubMed ID: 36455593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
    Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
    Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 'Netflix plus model': can subscription financing improve access to medicines in low- and middle-income countries?
    Cherla A; Howard N; Mossialos E
    Health Econ Policy Law; 2021 Apr; 16(2):113-123. PubMed ID: 32122423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compulsory Licensing of Pharmaceuticals in High-Income Countries: A Comparative Analysis.
    Qunaj L; Kaltenboeck A; Bach PB
    Milbank Q; 2022 Mar; 100(1):284-313. PubMed ID: 35257415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. University contributions to the HPV vaccine and implications for access to vaccines in developing countries: addressing materials and know-how in university technology transfer policy.
    Crager SE; Guillen E; Price M
    Am J Law Med; 2009; 35(2-3):253-79. PubMed ID: 19697749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
    Mermelstein S; Stevens H
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the political will exist to bring quality-assured and affordable drugs to low- and middle-income countries?
    Beck EJ; Mandalia S; DongmoNguimfack B; Pinheiro E; 't Hoen E; Boulet P; Stover J; Gupta A; Juneja S; Habiyambere V; Ghys P; Nunez C
    Glob Health Action; 2019; 12(1):1586317. PubMed ID: 30983547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?
    Assefa Y; Hill PS; Ulikpan A; Williams OD
    Global Health; 2017 Sep; 13(1):73. PubMed ID: 28903757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
    Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
    PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method for understanding generic procurement of HIV medicines by developing countries with patent protection.
    Beall RF; Attaran A
    Soc Sci Med; 2017 Jul; 185():118-126. PubMed ID: 28578209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could international compulsory licensing reconcile tiered pricing of pharmaceuticals with the right to health?
    Ooms G; Forman L; Williams OD; Hill PS
    BMC Int Health Hum Rights; 2014 Dec; 14():37. PubMed ID: 25518744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
    't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
    Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compulsory licensing often did not produce lower prices for antiretrovirals compared to international procurement.
    Beall RF; Kuhn R; Attaran A
    Health Aff (Millwood); 2015 Mar; 34(3):493-501. PubMed ID: 25732501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Negotiating public-health intellectual property licensing agreements to increase access to health technologies: an insider's story.
    Gore C; Morin S; Røttingen JA; Kieny MP
    BMJ Glob Health; 2023 Sep; 8(9):. PubMed ID: 37669799
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.